VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ALVOAlvotech
$3.68$1.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksALVOBalance Sheet

Alvotech (ALVO) Balance Sheet

6Y historyFree accessUpdated daily

The company maintains a vulnerable capital structure characterized by a persistent negative equity position of $282.3 million and a substantial $1.5 billion total debt burden as of 2026Q1.

ALVO Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20
Total Current Assets455.98M574.01M455.02M194.84M230.74M119.82M86.16M
Cash & Short-Term Investments63.83M172.36M51.43M11.16M66.43M17.56M31.69M
Cash Only63.83M172.36M51.43M11.16M66.43M17.56M31.69M
Short-Term Investments0000000
Accounts Receivable106.87M153.79M251.72M87.22M71.39M53.88M33.12M
Days Sales Outstanding78.0395.74187.63348.17313.82534.83181.45
Inventory228.02M220.05M127.89M74.43M71.47M39.06M9.65M
Days Inventory Outstanding342.42340.98251.9168.9407--
Other Current Assets26.18M000851K05.79M
Total Non-Current Assets965.19M913.08M766.38M755.25M597.71M478.16M388.26M
Property, Plant & Equipment495.23M356.4M409.74M356.58M268.1M205.33M176.97M
Fixed Asset Turnover1.25x1.65x1.20x0.26x0.31x0.18x0.38x
Goodwill12.51M12.84M11.33M12.06M11.64M12.37M13.43M
Intangible Assets119.59M81.83M20.62M19.08M25.65M21.51M6.33M
Long-Term Investments166.5M122.93M22.71M18.49M48.57M55.31M56.68M
Other Non-Current Assets14.96M146.87M3.62M39.23M34.25M13.23M134.85M
Total Assets1.42B1.49B1.22B950.09M828.44M597.98M474.42M
Asset Turnover0.39x0.39x0.40x0.10x0.10x0.06x0.14x
Asset Growth %80.5%21.75%28.56%14.68%38.54%26.04%-
Total Current Liabilities259.78M304.08M193.4M260.95M167.29M111.84M50.98M
Accounts Payable97.86M126.12M67.13M80.56M49.19M28.59M11.96M
Days Payables Outstanding168.78195.43132.22182.81280.11--
Short-Term Debt42.51M36.92M32.7M38.02M19.92M2.77M2.5M
Deferred Revenue (Current)150.17M30.36M15.98M59.18M36.91M29.69M0
Other Current Liabilities12.05M13.7M6.63M34.5M17.46M5.26M14.63M
Current Ratio1.76x1.89x2.35x0.75x1.38x1.07x1.69x
Quick Ratio0.88x1.16x1.69x0.46x0.95x0.72x1.50x
Cash Conversion Cycle251.66241.28307.31334.26440.71--
Total Non-Current Liabilities1.44B1.47B1.44B1.62B1.23B621.75M1.29B
Long-Term Debt1.27B1.26B1.04B922.13M744.65M398.14M565.4M
Capital Lease Obligations553.3M138M112.14M105.63M35.37M114.84M103.47M
Deferred Tax Liabilities24.59M7.87M1.81M53K309K150K0
Other Non-Current Liabilities21.76M53.99M210.22M520.55M388.22M63.77M621.82M
Total Liabilities1.7B1.77B1.63B1.88B1.39B733.59M1.34B
Total Debt1.46B1.45B1.19B1.08B805.1M523.05M676.85M
Net Debt1.39B1.28B1.14B1.06B738.67M505.5M645.16M
Debt / Equity-5.16x------
Debt / EBITDA13.35x12.49x11.79x----
Net Debt / EBITDA12.77x11.00x11.28x----
Interest Coverage0.13x1.91x-0.40x-3.84x-5.03x-0.32x-1.99x
Total Equity-282.31M-284.49M-412.77M-932.49M-564.42M-135.61M-867.24M
Equity Growth %157.65%31.08%55.73%-65.21%-316.2%84.36%-
Book Value per Share-0.85-1.02-1.54-4.10-2.85-4.34-27.75
Total Shareholders' Equity-282.31M-284.49M-412.77M-932.49M-564.42M-135.61M-867.24M
Common Stock2.93M2.93M2.83M2.28M2.13M135K73K
Retained Earnings-2.41B-2.41B-2.44B-2.21B-1.65B-1.14B-1.04B
Treasury Stock0000000
Accumulated OCI16.6M16.68M15.05M41.38M29.14M4.67M4.97M
Minority Interest0000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Persistent negative equity position

Persistent Negative Equity and Leverage

As reported in financial statements, Alvotech's balance sheet trajectory remains characterized by a persistent negative equity position, which deepened to negative $282.3 million in 2026Q1, reflecting the ongoing challenge of financing a capital-intensive biosimilar pipeline through debt rather than retained earnings or equity issuance.

The consistent negative equity suggests that the company's historical losses have eroded its capital base, leaving the balance sheet highly sensitive to further operational setbacks. Investors should monitor whether the company can transition toward positive retained earnings as its commercial portfolio matures, or if the current trajectory necessitates further dilutive financing.

High Leverage Constrains Financial Flexibility

Based on Alvotech's reported figures, total debt has remained elevated at $1.5 billion as of 2026Q1, indicating that the company relies heavily on external leverage to fund its specialized manufacturing infrastructure and R&D activities, which significantly limits its financial flexibility in a volatile interest rate environment.

The reliance on debt to support operations suggests that the company's capital structure is currently optimized for growth at the expense of solvency risk. This leverage profile warrants close investigation, as the interest burden may continue to pressure cash flows and hinder the company's ability to reinvest in its pipeline.

Liquidity Buffers Remain Highly Volatile

According to recent SEC filings, Alvotech's cash position has fluctuated significantly, dropping to $63.8 million in 2026Q1 from $172.4 million in 2025Q4, which highlights the company's vulnerability to timing mismatches between milestone-driven cash inflows and the ongoing, high-burn requirements of its biologics manufacturing operations.

The erratic nature of the current ratio, which has swung from 0.24 to 2.69 over the last ten quarters, suggests that liquidity management is heavily dependent on the timing of partnership payments. This volatility implies that the company may face periodic liquidity crunches if commercial milestones are delayed or if product uptake fails to meet expectations.

Capital Intensity of Manufacturing Infrastructure

As indicated by the provided data, net PPE has grown to $495.2 million by 2026Q1, reflecting the company's strategic commitment to maintaining a purpose-built, vertically integrated manufacturing facility in Iceland to support its biosimilar production requirements and maintain a competitive cost-of-goods-sold profile.

The concentration of assets in specialized manufacturing equipment suggests an asset-heavy business model that requires high capacity utilization to achieve profitability. Investors should consider whether this infrastructure investment will yield the expected margin expansion or if it will remain a drag on returns due to high fixed-cost overhead.

Deferred Revenue Signals Future Recognition

Based on the company's reported figures, deferred revenue stood at $22.7 million in 2026Q1, representing a decline from previous periods and suggesting that the pipeline of pre-paid milestone payments is being recognized as revenue, which may impact the predictability of future top-line growth.

The downward trend in deferred revenue may indicate that the company is exhausting its existing backlog of milestone-related obligations. This shift warrants further investigation into whether the company can successfully replace these one-time payments with consistent, recurring product sales to sustain its long-term revenue trajectory.

ALVO — Frequently Asked Questions

Quick answers to the most common questions about buying ALVO stock.

What are the total assets of Alvotech (ALVO)?

As of 2025, Alvotech (ALVO) had total assets of $1.49B including $574.0M in current assets.

How much debt does Alvotech (ALVO) have?

Alvotech (ALVO) carries total debt of $1.45B, offset by $172.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Alvotech?

Alvotech (ALVO) has total shareholders' equity (book value) of $-284.5M ($-1.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Alvotech's current ratio and liquidity?

Alvotech (ALVO) reported a current ratio of 1.89x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.